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Background: Statins are increasingly prescribed to prevent cardiovascular disease (CVD) in asymptomatic
individuals. Yet, it is unknown whether those at higher CVD risk – i.e. individuals in lower socio-economic position
(SEP) – are adequately reached by this high-risk strategy. We aimed to examine whether the Danish
implementation of the strategy to prevent cardiovascular disease (CVD) by initiating statin (HMG-CoA reductase
inhibitor) therapy in high-risk individuals is equitable across socioeconomic groups.
Methods:
Design: Cohort study.
Setting and participants: Applying individual-level nationwide register information on socio-demographics,
dispensed prescription drugs and hospital discharges, all Danish citizens aged 20+ without previous register-
markers of CVD, diabetes or statin therapy were followed during 2002–2006 for first occurrence of myocardial
infarction (MI) and a dispensed statin prescription (N = 3.3 mill).
Main outcome measures: Stratified by gender, 5-year age-groups and socioeconomic position (SEP), incidence of MI
was applied as a proxy for statin need. Need-standardized statin incidence rates were calculated, applying MI
incidence rate ratios (IRR) as need-weights to adjust for unequal needs across SEP.Horizontal equity in initiating
statin therapy was tested by means of Poisson regression analysis. Applying the need-standardized statin
parameters and the lowest SEP-group as reference, a need-standardized statin IRR > 1 translates into horizontal
inequity favouring the higher SEP-groups.
Results: MI incidence decreased with increasing SEP without a parallel trend in incidence of statin therapy.
According to the regression analyses, the need-standardized statin incidence increased in men aged 40–64 by 17%,
IRR 1.17 (95% CI: 1.14-1.19) with each increase in income quintile. In women the proportion was 23%, IRR 1.23
(1.16-1.29). An analogous pattern was seen applying education as SEP indicator and among subjects aged 65–84.
Conclusion: The high-risk strategy to prevent CVD by initiating statin therapy seems to be inequitable, reaching
primarily high-risk subjects in lower risk SEP-groups.
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A steep inverse relationship between socioeconomic
position (SEP) and incidence of cardiovascular disease
(CVD) has consistently been shown across high-income
Western countries [1-3]. The social gradient has
widened over the last decades [4,5] and is to a large ex-
tent mediated by the conventional risk factors (i.e.,
smoking, high blood pressure and serum cholesterol) –
when evaluated in absolute terms [1,6-8]. This holds also
for the most important CVD component, myocardial in-
farction (MI) [9].
As CVD is one of the leading causes of premature
death in the Western world, preventive strategies are on
political agendas, all focusing on the conventional risk-
factors, either through their socio-cultural determinants
(population (structural) strategies) or through individual
behaviour/risk-factors, such as the high-risk strategy to
prevent CVD in general practice. In the high-risk strat-
egy (often termed ‘primary prevention’), asymptomatic
individuals are screened to determine the need for pre-
ventive interventions, such as antihypertensives or lipid
lowering drugs (almost exclusively statins). In the
present study, we focus on statins (HMG-CoA reductase
inhibitors), introduced in 1994 [10] to, reduce post-MI
mortality in middle-aged men with hypercholesterol-
emia. Following subsequent randomised clinical trials
(RCTs), recommendations for statins have broadened,
including now also asymptomatic individuals (i.e., with-
out established CVD or diabetes) irrespective of lipid-
levels age and gender. “The question of ‘at what lipid
level to initiate treatment’ has to be replaced by ‘at what
cardiovascular risk should statins be started’“[11].
The high-risk strategy has been implemented in
Denmark as an opportunistic screening strategy i.e. cli-
ents who show up in the general practitioner’s (GP)
office may be screened for high CVD risk for possible
prescription of preventive drugs. In line with the Euro-
pean guidelines and the European Systematic Coronary
Risk Evaluation [12], Danish GPs are recommended to
use a matrix of serum lipid and blood pressure levels
(stratified by age, gender and smoking status) for identi-
fying high-risk individuals, applying an estimated
10-year risk of fatal atherosclerotic events above 5% as
high risk threshold. While risk thresholds and CVD end-
points vary slightly according to country, all risk-score
charts are based on the same risk-factor matrix, provid-
ing risk estimates based on data and risk-equations from
historic cohort studies and RCTs [12-14].
The Danish health care system is mainly tax-financed
and based on the egalitarian principle, with equal health
care (access/treatment/outcome) for equal (legitimate)
health care needs [15] – also called horizontal equity
[16]. While authorized GP services are free, prescription
drugs require patient co-payment. Based on decisions byan authority under the Ministry of Health, the actual
amount of reimbursement depends on whether a par-
ticular drug is reimbursable and the actual reimburse-
ment schedule for reimbursable drugs [17]. The current
‘need-dependent’ reimbursement schedule (introduced
March 2000) has a number of reimbursement levels, the
reimbursed percentage increasing stepwise with the indi-
vidual’s annual drug expenditures. Reimbursement is
based on the cheapest generic drug [17]. Despite near
universal health care coverage in many European coun-
tries, income-related inequalities in the use of physician
services have been observed [18-20]. In Denmark this
holds true especially in regards to elective procedures
[21] and services with co-payments, such as prescription
drugs [22-24]. Yet, European health-care systems are
under pressure due to increasing health care expendi-
tures and the challenges of an ageing population [25,26],
which includes shortage of GP’s partly due to the retire-
ment of the baby-boom generation.
There is an ongoing debate about the high-risk strat-
egy [14,27-29], encompassing allocation of scarce health
care resources [28] and “The strategy of preventive
medicine”, by Geoffrey Rose [30], i.e., the high-risk strat-
egy versus the population strategy [29,31,32]. As reduc-
tion of social inequalities in health is a central goal in
WHO and EU programmes [33,34], it is also being
debated whether or not these strategies will reduce in-
equalities in CVD [35,36]. A range of studies have
explored inequalities in utilisation of CVD drugs, but
without explicitly taking need-determined measures into
account, some focusing on regional or socioeconomic
inequalities [37-40], others restricting analyses to indivi-
duals with the same medical condition [23,41]. In a
study of equity in statin prescribing by GPs in the UK,
the authors explore to what extent prescribing variations
in different primary care trusts are associated with the
frequency of CVD admissions and socio-demographic
characteristics [38]. Assuming implicitly equal needs
across these groups, the results of the UK study could
indicate inequitable statin prescribing. Yet, inequality in
health care delivery can only be interpreted as inequity if
legitimate need-determined inequalities are taken into
account [19,20].
In the present study, we focus on initiation of prevent-
ive statin therapy in the high-risk strategy as implemen-
ted in Denmark. Due to the social gradient in incidence
of CVD we expect an increasing need for CVD prevent-
ive drugs with decreasing SEP i.e. unequal needs across
socioeconomic groups. In line with other studies focus-
ing on equity in health care delivery [22,42], we assume
that equity will be met if care is provided proportionally
to the need. To our knowledge no studies has explored
to what extent the high-risk strategy to reduce CVD is
equitable.
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nish implementation of the strategy to prevent CVD by
initiating statin therapy in high-risk individuals is equit-
able across socioeconomic groups; hypothesising that
this high-risk strategy will not adequately reach groups
with a lower SEP, characterised by having a higher risk
of CVD.
Methods
Data source and participants
From nationwide Danish registers maintained by the Na-
tional Board of Health and Statistics Denmark, we
retrieved individual-level information on dispensed pre-
scription drugs, hospital discharges, dates of death or
emigration, and socioeconomic indicators. Data were
linked by means of a unique encrypted person-identifier,
allowing authorised researchers to follow individuals in
multiple individual-level registries hosted in Statistics
Denmark. Register-based studies in Denmark do not re-
quire approval by an ethics board.
A cohort corresponding to all Danish citizens aged 20
+ without previous register markers of CVD, diabetes or
statin treatment were followed, during 2002–2006, in
the registries, for dispensed statin prescriptions and the
first occurrence of MI (N= 3.3 mill). We applied two dif-
ferent SEP indicators: disposable family income and
highest attained education (as of 2002). Table 1 shows
the characteristics of the cohort of asymptomatic indivi-
duals, by gender, age and highest attainted education,
demonstrating that historical information on education
is poorly covered among persons older than 75.Table 1 The cohort as of January 1, 2002, according to gende
Gender Educational
Levela
20-39 40-54 55-64
N (%) N (%) N
Male 1 (Basic) 215,607 (32) 120,082 (24) 79,745
2 229,083 (34) 210,144 (42) 108,985
3 134,755 (20) 50,034 (10) 15,949
4 (High) 80,853 (12) 95,065 (19) 50,505
Missing 20,213 (3) 25,017 (5) 10,633
All 673,773 500,343 265,81
Female 1 (Basic) 171,753 (27) 141,319 (29) 109,669
2 190,837 (30) 160,811 (33) 95,961
3 146,308 (23) 38,984 (8) 13,709
4 (High) 114,502 (18) 126,700 (26) 46,609
Missing 19,084 (3) 24,365 (5) 8,225
All 636,122 487,306 274
Both Total 1,309,895 987,646 539
Danish residents without register markers of CVD, diabetes and/or statin treatment.
a) Educational levels:
1) 7–10 years basic school, 2) Vocational training after basic school, 3) High school
higher education.From the Danish National Patient Registry, we
retrieved information on patient discharge from non-
psychiatric hospitals since 1977. Records include the ad-
mission and discharge dates, discharge diagnoses accord-
ing to the International Classification of Diseases (ICD),
8th revision until 1993, and 10th revision thereafter (9th
revision has not been used in Denmark) along with
codes for diagnostic and surgical procedures. We
included main and secondary diagnoses for admitted
patients and patients in ambulatory care. From the
Registry of Causes of Death, we retrieved date and cause
of death (primary and contributory).
Information on dispensed prescription drugs was
retrieved from the Danish National Prescription Registry
(DNPR), containing full information since 1996 on all out-
of-hospital purchases of prescription drugs at Danish phar-
macies including those of nursing home residents [43].
Records include the person identifier, date of dispensing,
and the Anatomical Therapeutic Chemical (ATC) classifica-
tion code of the dispensed drug [44]. From the DNPR we
retrieved information on dispensed cardiovascular drugs
(ATC groups C and B01) and antidiabetics (A10).
To identify asymptomatic individuals, we applied
historical register data on in/out-patient diagnoses and
procedures along with dispensed prescription drugs as
register-markers for a range of CVD conditions, including
ischemic heart disease (IHD) with or without myocardial
infarction (MI), stroke, a range of other atherosclerotic
conditions, and diabetes. We define asymptomatic indivi-
duals as individuals without register-markers of CVD or
diabetes, as defined in a recent publication [45].r, age and educational level
65-74 75-84 85+ All
(%) N (%) N (%) N (%) N
(30) 53,249 (42) 25,022 (43) 131 (1) 493,837
(41) 46,910 (37) 13,966 (24) 0 (0) 609,087
(6) 5,071 (4) 1,746 (3) 0 (0) 207,555
(19) 17,750 (14) 6,401 (11) 262 (2) 250,836
(4) 2,536 (2) 10,474 (18) 12,722 (97) 81,594
6 126,784 58,190 13,115 1,638,021
(40) 91,760 (59) 52,508 (55) 320 (1) 567,329
(35) 40,437 (26) 15,275 (16) 0 (0) 503,320
(5) 4,666 (3) 1,909 (2) 0 (0) 205,576
(17) 17,108 (11) 5,728 (6) 0 (0) 310,647
(3) 3,111 (2) 20,048 (21) 31,359 (98) 106,192
,173 155,525 95,469 31,999 1,680,594
,989 822,298 101,359 45,114 3,318,615
or 9/10 years basic school with 1 year higher education 4) More than two years
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While measures such as the Gini-coefficient of inequality,
concentration index and the slope index of inequalities
provide means for quantifying the degree of for example
income-related inequality in health or health care delivery
[46], a measure combining potential inequalities both in
health care delivery and health care needs is indispensable
to quantify inequities in health care delivery – if needs also
are unequal across strata. However, measuring the need
for preventive health care is a challenge, as such needs not
may be captured by for example self-rated health scales.
We opted to apply a need-proxy analogous to the under-
lying presumption of the risk-score chart, namely a meas-
ure of CVD- incidence in the background population of
asymptomatic individuals, i.e. without CVD, diabetes or
statin therapy - stratified by gender, 5-year age groups and
SEP indicator.
Due to the high validity of the diagnosis of MI in the
Danish registries [47], we applied the incidence of MI asTable 2 Observed and need-standardized incidence of statin
gender, age-group and SEP indicators
Gender SEP 40-54 55-64
Need Statin incidence d Need Statin
Weight c Observed St.
dized e
Weight ObservINCOME a
Male 1 (Low) 1.00 8.0 8.0 1.00 16.0
2 0.90 9.0 10.0 1.01 19.1
3 0.91 9.8 10.7 0.90 20.3
4 0.82 10.2 12.4 0.80 21.2
5 (High) 0.71 10.5 14.9 0.70 21.3
Female 1 (Low) 1.00 8.3 8.3 1.00 23.5
2 0.80 8.3 10.4 0.85 25.2
3 0.64 8.4 13.1 0.64 24.7
4 0.60 8.5 14.1 0.57 23.1
5 (High) 0.49 7.6 15.6 0.31 20.7
EDUCATIONb
Male 1 (Basic) 1.00 9.4 9.4 1.00 18.7
2 0.81 10.2 12.6 0.89 20.6
3 0.59 8.3 14.1 0.75 18.5
4 (High) 0.50 8.8 17.8 0.66 19.9
Female 1 (Basic 1.00 9.9 9.9 1.00 25.6
2 0.63 8.8 14.0 0.68 23.8
3 0.43 6.0 14.0 0.47 18.7
4 (High) 0.34 6.2 18.2 0.38 19.1
a) Quintiles of disposable family income within gender and 5-years age-groups – in
b) Educational levels, cf. notes in Table 1.
c) Incidence Rate Ratio of myocardial infarction (MI-IRR) among asymptomatic indiv
group.
d) Incidence of statin therapy among asymptomatic individuals: 1000*(Number inci
e) Need-standardized statin incidence (‘St.dized’): Observed statin incidence/MI-IRR.need-proxy, using two alternative need-proxies in a sen-
sitivity analysis: first stroke or MI as combined CVD
endpoint and CVD as cause of death (MI, stroke or aor-
tic aneurysm). Stratum specific MI-incidence rates were
calculated, corresponding to number of incident MI
cases (hospitalised or fatal) per 10,000 person-years at
risk (PYR) during 2002–2006, censoring at death, emi-
gration and register-markers of CVD, diabetes or statin
therapy. Analogously, we calculated the ‘observed’ inci-
dence of statin therapy (number redeeming the first sta-
tin prescription/10,000 PYR – censoring at death,
emigration and register-markers of CVD or diabetes)
and the combined MI-stroke endpoint. In order not to
confine CVD-mortality to sudden CVD-death, CVD-
mortality was calculated without censoring for new
events of CVD or diabetes, covering also a longer span
of time (2002–2008).
We applied a fixed SEP level corresponding to the be-
ginning of the observation period (primo 2002). In ordertreatment among asymptomatic individuals, according to
65-74 75-84
incidence Need Statin incidence Need Statin incidence
ed St.
dized
weight Observed St.
dized
weight Observed St.
dized
16.0 1.00 18.6 18.6 1.00 10.2 10.2
18.9 0.96 22.2 23.2 0.81 10.9 13.5
22.5 0.89 23.3 26.1 0.85 11.2 13.2
26.4 0.79 23.2 29.3 0.77 12.6 16.3
30.5 0.65 23.4 35.8 0.66 15.0 22.8
23.5 1.00 28.2 28.2 1.00 14.1 14.1
29.8 0.85 29.4 34.6 0.90 15.3 17.1
38.8 0.90 28.8 32.0 1.02 15.6 15.3
40.5 0.69 29.2 42.0 0.82 17.7 21.6
67.0 0.44 28.2 63.4 0.64 17.5 27.5
18.7 1.00 20.5 20.5 1.00 11.6 11.6
23.2 0.97 23.9 24.6 0.94 14.6 15.6
24.6 0.82 22.1 27.0 0.76 13.9 18.2
30.2 0.65 23.8 36.7 0.72 15.7 21.8
25.6 1.00 28.9 28.9 1.00 17.3 17.3
35.2 0.79 30.0 38.1 0.82 20.2 24.7
39.6 0.54 25.2 46.3 0.68 17.2 25.3
50.8 0.53 26.4 50.2 0.65 19.0 29.5
flated average over 1996–2001.
iduals, applying lowest SEP group (within gender and age-group) as reference
dent statin dispensing/person years at risk).
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the average annual income between 1996 and 2001
(inflated to 2000 purchasing power), divided into income
quintiles within gender and age group. The highest
attained educational levels as of 2002 were divided into
four groups according to length of formal education, cf.
Table 1. As the analysis covers a time span of five years,
individuals were considered to belong to a fixed 5-year
age-group (i.e., that of 2002).
To evaluate horizontal inequity in initiation of pre-
ventive statin therapy, we adjusted the observed inci-
dence of statin therapy according to the different
needs across SEP-groups, applying stratum specific
MI-incidence as proxy for needs. By means of indirect
standardisation, we calculated the expected incidence
of statin therapy (‘need-standardized statin incidence’),
assuming that incidence of statin therapy must in-
crease proportionally to the need across SEP-groups -
for equity to be met. The need-standardized statin
incidence was calculated as the observed statin inci-
dence divided by the stratum specific need weights cor-
responding to the incidence rate ratio of MI (MI-IRR),
Table 2. The denominator (PYR) of the observed statin
incidence rather than the nominator (number of
events) was need-standardized, dividing the observed
PYR by MI-IRR.
Based on the need-standardized statin incidence para-
meters (observed statin events (counts), need-
standardized PYR (exposure)), Poisson regression ana-
lyses were applied to test the overall horizontal equity
across SEP. With the lowest SEP-group (and age group)
as reference, a need-standardized statin-IRR> 1 translates0
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Figure 1 Incidence of statin therapy versus incidence of myocardial ininto horizontal inequity favouring the higher SEP-groups.
The null hypothesis, horizontal equity, corresponds
thus to statin-IRR= 1. We estimated a ‘horizontal in-
equity gradient’ (the overall linear trend) reflecting the
increase in need-standardized statin-IRR for each in-
crease in SEP. Owing to a gender and age specific pat-
tern of both MI-incidence (need) and incidence of
preventive statin therapy, we stratified the analyses
according to gender and ages +/−65, cf. Figure 1.
Nonparametric bootstrapping [48] was applied to
incorporate the precision of the need-weights in the
confidence intervals (CI) of the need-standardized
statin IRR. Based on 10,000 bootstrap replications,
need-weights were calculated and applied in the Pois-
son regression analyses of need-standardized statin
incidence parameters. Normal based 95% CI from
the bootstrapping procedure were applied as CI for
the point estimate for statin IRR calculated from the
original data.
All analyses were performed using Stata Release 11.1
(StataCorp, College Station, TX, USA). Access to data
was provided and secured through collaboration be-
tween the University of Copenhagen and Statistics Den-
mark. Register-based studies in Denmark do not
require approval by an ethics board.
Results
Figure 1 depicts the incidence of MI and statin therapy
among asymptomatic individuals during 2002–2006
according to age, stratified by gender. Both in men and
women, the MI-incidence increases gradually with age,
whereas statin incidence increases steeply until the age0
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farction during 2002–2006 in asymptomatic individuals.
Table 3 Result of Poisson regression analysis, testing horizontal equity across levels of socio-economic position (SEP)
with differential needs
SEP indicator a Age 40-64 Age 65-84
Male Female Male Female
Income Quintiles IRR b 95% CI c IRR 95% CI IRR 95% CI IRR 95% CI
1 1.00 1.00 1.00 1.00
2 1.22 (1.10-1.35) 1.27 (1.04-1.55) 1.27 (1.05-1.54) 1.25 (1.04-1.51)
3 1.38 (1.29-1.48) 1.63 (1.39-1.92) 1.38 (1.17-1.63) 1.16 (0.93-1.45)
4 1.61 (1.47-1.76) 1.73 (1.40-2.15) 1.58 (1.36-1.84) 1.54 (1.27-1.86)
5 1.89 (1.70-2.10) 2.44 (1.86-3.21) 1.99 (1.68-2.35) 2.26 (1.80-2.80)
HIE gradient d 1.17 (1.14-1.19) 1.23 (1.16-1.29) 1.17 (1.14-1.20) 1.20 (1.14-1.27)
Educational level IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
1 1.00 1.00 1.00 1.00
2 1.29 (1.17-1.42) 1.38 (1.27-1.49) 1.19 (1.07-1.33) 1.33 (1.13-1.56)
3 1.40 (1.18-1.66) 1.49 (1.33-1.65) 1.34 (1.19-1.52) 1.52 (1.23-1.89)
4 1.74 (1.51-2.01) 1.90 (1.72-2.09) 1.77 (1.59-1.97) 1.70 (1.47-1.97)
HIE gradient 1.19 (1.15-1.24) 1.24 (1.19-1.29) 1.21 (1.17-1.25) 1.21 (1.14-1.28)
a) Indicators of SEP: Quintiles of disposable income and 4 levels of formal education, cf. notes Table 1.
b) Poisson regression analyses of need-standardized statin Incidence Rate Ratio (IRR), applying need-standardized statin incidence parameters within gender and
5-year age-groups, based on indirect standardization with Incidence of myocardial infarction in the background population as need-weights, cf. Table 2.
c) Bootstrapping (10,000 reps.) is applied for 95% confidence intervals (CI).
d) Horizontal Inequity (HIE) gradient: The relative change in need-standardized statin incidence for each increase in SEP, i.e., the estimated overall linear trend.
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incidence is highest among men of all ages, the opposite
is the case as regards statin incidence.
Table 2 shows that the need-weights (MI-IRR relative
to the lowest SEP-group) are decreasing with increasing
SEP – independently of gender and age categories. In
men aged 55–64, the need (MI-incidence) in the highest
income quintile is 70% of that in the lowest income
quintile, in women the figure is 30%. Above the age of
75 the gradient is less pronounced. Analogously, when
applying four educational levels as an indicator for SEP,
the need in men aged 55–64 with the highest educa-
tional level is 70% of those with basic education – inTable 4 Sensitivity analysis of horizontal equity in incidence
need-weights (need-proxies) in the need-standardized analys
or CVD-death b
SEP indicator c Age Horizontal Ineq
MI
Male Female
Income 40-64 1.17 1.23
65-84 1.17 1.20
Educational level 40-64 1.19 1.24
65-84 1.21 1.21
a) Need-standardized Poisson analyses see notes Table 3.
b) Myocardial infarction (MI) as need-weight in the basic analyses. Two alternative C
2006, and CVD-death (i.e., MI, stroke and aorta-aneurism) during 2002–2008.
c) Indicators of socio-economic position (SEP): cf. notes Tables 1 & 3.
d) Horizontal Inequity (HIE) gradient: The relative change in need-standardized statiwomen the figure is 40%. Yet, while the observed statin
incidence increases with increasing income in men, only,
the need-standardized statin incidence increases steeply
with increasing income in both genders – and more so
among women due to the steeper gradient in MI-
incidence.
Table 3 presents the results of the gender/age stratified
Poisson regression analyses on need-standardized statin
parameters. In men aged 40–64, the need-standardized
statin incidence increases by 17% (IRR 1.17; 95% CI
1.14-1.19) for each increase in income quintile – corre-
sponding to the horizontal inequity gradient (HIE-gradi-
ent). In women the HIE gradient is greater 23% (1.23;of preventive statin therapy: Three alternative
es a: Myocardial infarction (MI), combined MI-stroke
uity gradient (IRR)d dependent on need-weights
MI-stroke CVD-death
Male Female Male Female
1.18 1.15 1.39 1.36
1.15 1.10 1.29 1.23
1.18 1.11 1.33 1.22
1.15 1.11 1.23 1.29
VD need: Incidence of MI and stroke as combined endpoint during 2002–
n incidence for each increase in SEP, i.e., the estimated overall linear trend.
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sponding HIE-gradient is 17% (1.17; 1.14-1.20) and 20%
(1.20; 1.14-1.27), in men and women, respectively.
The HIE-gradient concerning educational level reveals
a similar pattern, i.e., 19% (1.19; 1.15-1.24) in men aged
30–64, and 24% (1.24; 1.19-1.29) in women.
Table 4 shows sensitivity analysis of the need-proxy,
where the HIE-gradient is calculated applying the ori-
ginal need-proxy, MI incidence, as well as the two alter-
native need-proxies: MI/stroke as combined end-point
and CVD as cause of death, respectively. Independently
of need-weights (need-proxy) used, the sensitivity ana-
lysis revealed the same pattern of horizontal inequity,
favouring the better-off. Yet, the HIE-gradient is attenu-
ated when applying MI/stroke as a combined end-point.
This is particularly true for women. Conversely, the
HIE-gradient is enhanced when applying CVD-death as
need-proxy – especially among men.Discussion
Principal findings
Applying indirect standardisation and MI-incidence as a
proxy for need, we developed a pharmacoepidemiologi-
cal method to explore horizontal equity in initiation of
preventive statin therapy across SEP-groups with un-
equal needs, adjusting the observed statin incidence
according to relative needs across socio-demographic
groups. Our study indicates that the high-risk strategy
(as implemented in Denmark) to prevent CVD by initi-
ating preventive statin therapy is inequitable, reaching
primarily high-risk individuals in low-risk SEP-groups.
The favouring of more advantaged groups holds for both
genders, independently of applying income quintiles or
educational level as SEP indicator. In men aged 30–64,
the need-standardized statin incidence increased by 17%
for each increase income quintile (the horizontal in-
equity gradient) – in women the increase was 21%.
Only among men, the observed incidence statin ther-
apy tended to increase with increasing SEP, but due to a
steeper social gradient in MI-incidence among women,
the horizontal inequity gradient of initiating preventive
statin therapy was steepest in women.Strengths and limitations
Given the inverse relationship between SEP and
CVD, the challenge of this study examining equity in
the medicamental high-risk strategy to prevent CVD
was twofold: firstly, to operationalize need and equity
in CVD preventive drug therapy across SEP-groups
with unequal needs, and secondly, to develop appro-
priate pharmacoepidemiological methods for testing
horizontal equity.Needs
We opted to apply nationwide register data on MI-
incidence in the statin free and asymptomatic back-
ground population stratified by gender, age and SEP as
need-proxy, instead of calculating individual-level CVD-
risk based on survey information on CVD-risk factors
and risk scoring,
This is a strength for at least three reasons:
1) The nationwide approach is without the well-known
selection bias problems from cohort studies/surveys
where people are invited to participate.
2) The risk-score charts generally have low predictive
value – both at the individual and the group level.
Various cohort studies indicate that standard risk-
score charts tend to underestimate CVD-risk in
worse-off groups, overestimating the risk in better-
off groups [36,49,50], and attempts have been made
to modify risk-score charts according to the actual
background populations [51] and/or socioeconomic
groups [49,50]. Yet, individual risk prediction is
notoriously difficult [52,53], and as most CVD
events occur in people with modest risk-factor
values, overlapping with those seen in people
without CVD, the appropriateness of applying
individual risk-factor levels as a screening tool has
been questioned [52,54,55]. The risk-score charts
applied in Denmark seems, in fact, to have a very
poor predictive value [56]. In the present study we
applied risk (MI-incidence) at the sub-group level
(gender, age and SEP) as need-proxy rather than risk
at the individual level. Yet, individual risk estimates
based on risk-scoring relies on risk calculated at the
group level (age and gender) from historic survey
data.
3) Register-based information on MI-diagnoses is
regarded as valid in-hospital diagnosis information
[47]. Thus, the estimated MI-incidences should
reveal the actual SEP gradient in MI-incidence.
However, due to potential differential symptom
awareness and communication barriers, a social
gradient in admission for MI may exist, leading to
an underestimated MI-incidence in less advantaged
groups. The better-off, on the other hand, may be
more likely to prevent MI by means of invasive
coronary procedures, leading to a potential
underestimated MI-incidence here. Yet, including
acute invasive coronary procedures as marker for
MI revealed the same results (data not shown).
Thus, we regard this bias of minor importance. In a
sensitivity analysis, stroke/MI as a combined
endpoint and CVD-death were tested as two
alternative need-proxies. Independently of need-
measure, the sensitivity analysis demonstrated
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applying the combined endpoint, the horizontal
inequity gradient was – especially in women –
attenuated, presumably due to a less pronounced
social gradient in the incidence of stroke than in
MI-incidence. Applying CVD-death as a need-proxy
(corresponding to the risk measure applied in
Danish risk-scoring charts), the horizontal inequity
was enhanced. Yet the ‘validity’ of actual MI-
incidence as the need-proxy rests upon the
assumption that the need for statin therapy is a
question of CVD-risk rather than a single risk-factor
level – and partly on the finding that conventional
risk-factors to a large extent mediate the social
gradient in CVD-risk (in absolute terms). However,
high cholesterol level has not consistently been
found to increase with decreasing SEP [6,8,57],
potentially explained by the rather imprecise
cholesterol parameters applied: risk thresholds for
cholesterol levels and measurement of total
cholesterol without distinguishing between the
various lipid-fractions. Conversely, other studies
have demonstrated an association between the
metabolic syndrome (caused by physical inactivity,
unhealthy diets, and obesity) and elevated low-
density lipid cholesterol (LDL) [58], indicating that
the inverse social gradient in LDL may follow the
social stratification in physical inactivity and obesity.Pharmacoepidemiological method for testing equity
Analogous to studies within economic equity research
[19,22,42], we applied indirect standardisation to evalu-
ate horizontal equity in health care delivery. In a study
on equity in US ambulatory care [42], the number of
ambulatory visits was adjusted according to differential
self-rated health. Applying the need-standardized
counts of the dependent variable (ambulatory visits)
and a continuous income variable as the explanatory
variable, a ‘horizontal inequity index’ (i.e., a need-
standardized concentration index) was estimated. In
our pharmacoepidemiological approach, we calculated,
instead, a need-standardized incidence rate of statin
therapy. Applying need-standardized statin incidence
parameters as a dependent variable and a SEP indica-
tor as an ordinal explanatory variable (e.g., income
quintiles), we estimated a horizontal inequity gradient.
We consider this methodological analogy to be a
strength. Yet, while it is intuitively reasonable to ‘ad-
just’ for differential health conditions when evaluating
horizontal equity in ambulatory visits, it may be less
obvious that incidence of preventive CVD-drug ther-
apy should be proportional to the risk of disease for
equity to be met.Interpretation and comparison with other studies
While a range studies have demonstrated inequality in
prescription of CVD preventive drugs [23,59-61], no stud-
ies have examined and quantified inequities, including
both prescribing patterns and needs in a nationwide per-
spective. In contrast to a Norwegian health survey study
[40] showing a decreasing trend of incidence of statin
treatment by increasing education in individuals without
reported CVD or diabetes at baseline, we found almost
the same incidence across educational groups among
asymptomatic individuals, censoring for new onset of
CVD/diabetes. The lack of censoring for onset of disease
in the Norwegian study most likely explains the discrep-
ancy between the studies, as lower SEP individuals are at
higher risk of developing disease and may thereby be mis-
classified as free of CVD or diabetes when initiating statin
treatment. Our finding that the high-risk strategy as
implemented in Denmark seems to be inequitable may re-
flect both the poor predictive value of the applied risk-
score charts and a selective uptake. The latter being an in-
herent consequence of applying an opportunistic screen-
ing strategy, where uptake depends on the client’s
participation and the physician’s general judgement of
her/his client. A so-called ‘healthy user effect’ has been
shown in pharmacoepidemiological studies, indicating that
preventive measures (e.g., vaccinations and drugs) tend to
be used by population segments with a broad spectrum of
healthier behaviours [62]. With the consistently shown so-
cial gradient in CVD in most Western countries, our find-
ings are likely to be applicable in other settings applying
an opportunistic screening strategy. Several studies have
demonstrated a socioeconomic gradient in screening up-
take [63], indicating both financial (due to drug co-pay-
ment) and psychosocial barriers in socially deprived
groups [64]. Psychosocial barriers to CVD screening may
include negative perceptions about screening tests, risk
perceptions and the social stress associated with talking
about unhealthy lifestyles with the GP – of higher SEP.
Our findings may also reflect that high CVD risk in lower
SEP at first hand is ‘attacked’ by encouraging individual
lifestyle modifications.
In line with other studies [61,65] our study indicates
that the high-risk strategy may widen the socioeconomic
gradient in CVD owing to the inequitable uptake. How-
ever, any widening of the CVD incidence gradient
depends on the outcome of therapy and not merely on
initiation of therapy. Here two other issues are import-
ant: Differential adherence to therapy and differential
outcome of therapy. In fact, long-term adherence to sta-
tin treatment is disappointing [66] – and is likely to de-
pend on SEP, indication and experienced adverse effects
(potentially weighted against the perceived beneficial ef-
fect). While the risk of life-threatening adverse effects is
low (e.g., rhabdomyolysis), various degrees of muscle
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ness to rhabdomyolysis [67]. If both incidence and dur-
ation of therapy are lowest among less advantaged
groups – the social gradient in prevalence and outcome
of therapy is likely to be even steeper than the gradient
found as to initiation of therapy. However, being
exposed to multiple risk factors (known and unknown)
acting in concert, socially disadvantaged groups may be
more vulnerable to high LDL levels than the better-off.
Hence, the outcome or beneficial effect of lifelong pre-
ventive statin therapy may be greater in less advantaged
groups – provided adherence to therapy.
Unanswered questions and future research
Various incentives have been proposed to enhance ad-
herence, requiring often GPs to be more actively
involved [68,69]. In a forthcoming study on the same na-
tionwide Danish data we explore potential socioeco-
nomic differences in adherence to statin treatment in
asymptomatic individuals.
The incidence of preventive statin treatment in this
study was found to peak around the age of 65, and to
decrease steeply hereafter. This pattern may reflect the
widespread use of the risk-score charts, covering the age
range of 40–65, potentially representing an issue of age-
ism. The finding that statin incidence is considerably
higher in asymptomatic women than men although MI-
incidence is higher in men (cf. Figure 1) may both reflect
a consequence of an opportunistic preventive screening
strategy and an overestimation of CVD-risk in Danish
women, corresponding to the finding in a Norwegian
study [70]. Both matters will require further research.
In contrasts to the opportunistic screening strategy ap-
plied in Denmark, a universal screening programme to
prevent CVD is actually being implemented in the UK
[71]. Here, all asymptomatic individuals aged 40–74 are
invited for risk-scoring and potential preventive statin
therapy. Yet, there is an ongoing discussion about the
programme covering both resource implications [72] and
the dilemma between a targeted high-risk strategy with a
high CVD risk threshold for initiating therapy with poten-
tially non-generic more potent and effective statins versus
a “population strategy” in which all invited individuals
should be prescribed low-price preventive treatment (gen-
eric statins) [71] or eventually a Polypill (a combination of
four CVD-preventive drug categories) [73,74],bypassing
the risk-scoring charts of poor predicative value and po-
tentially also subsequent GP visits. While recent cost-
effectiveness reviews indicate a very high cost effectiveness
of Polypill strategies [75], a pilot project may uncover
equity concerns before implementation of a general
screening strategy. Another strategy could be to focus the
high-risk drug strategy on middle-aged asymptomatic
men in whom the beneficial effect of preventive statintreatment is best documented, testing various settings in
order to reach lower SEP groups before implementation -
potentially also adjusting the reimbursement system ac-
cordingly. Yet, by not controlling the causes of high CVD
incidence (e.g., low cigarette prices; high levels of saturated
and trans-fats, sugars, salt hidden in processed foods, and
environmental factors) this ‘population’ strategy will be
palliative and not radical as structural/population strat-
egies tends to be [55]. Proposing a range of actions to be
taking, a newly published Danish report “Health inequality
- determinants and policies” [76] demonstrates that redu-
cing health inequality is not primarily a health care task,
but a complex task requiring coordinated efforts from dif-
ferent sectors (e.g. the education, social, healthcare, and
employment sectors).
Conclusions and implications for policy and
practice
Our study indicates that the high-risk strategy to prevent
CVD by means of preventive statin therapy – as practiced
in Denmark – is inequitable, primarily reaching high-risk
individuals in low-risk groups, i.e., individuals in higher
SEP-groups. The inequity is likely to be the consequence
of using a screening tool with low predictive value and a
screening programme with differential socioeconomic up-
take. Provided long-term adherence and a beneficial effect
of preventive statin therapy independent of SEP, the strat-
egy may contribute to accentuating the inverse relation-
ship between SEP and CVD. Facing the challenges posed
by an ageing population, one might question to what ex-
tent scarce GP resources should be allocated for better-off,
asymptomatic individuals.
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